Clinicians and researchers are currently unable to distinguish at diagnosis with sufficient confidence men with indolent prostate cancer (CaP) from those who have aggressive disease. At present, the strongest predictor of lethal CaP is Gleason score. Utilizing gene expression array data, we previously identified a 157 gene mRNA signature that distinguished high from low Gleason score. This signature significantly improved prediction of lethal disease among men with clinically heterogeneous Gleason score 7. The signature may have clinical utility, but before applying it to patients it must be further refined and then tested in biopsy specimens to determine if the predictive accuracy is sufficient to influence treatment decisions at the time of diagnosis. This mRNA study also identified metabolic pathways differentially enriched in high and low grade disease, generating hypotheses for biological mechanisms that may underlie CaP differentiation and clinical progression. Since different types of biological data may add to the mRNA signature as well as provide different biological information, it is worthwhile to further investigate the metabolic pathways identified. We therefore propose to build upon our promising expression profiling findings with the following Specific Aims: 1) Preparation and testing of Gleason signature of lethal disease for clinical use -To determine if the mRNA signature can be applied in the clinic, we will further validate it by testing its predictive accuracy in biopsy specimens at the time of diagnosis. We hypothesize that within Gleason score 7, the signature's ability to predict lethal disease may improve if applied specifically to the grade 3 or grade 4 focus of the tumor 2) Metabolomics bf Gleason grade In tumor as predictor of lethal disease - Our mRNA study identified metabolic pathways (pyrimidine, propanoate, and beta-alanine metabolism) differentially enriched in high and low grade tumors. Our preliminary data suggests these same pathways may be differentially enriched using metabolomic data;we hypothesize that metabolites may themselves be associated with Gleason score and lethal disease. 3) Metabolomics of Gleason grade in serum as biomarker for upgrading - We hypothesize that metabolites in serum associated with Gleason grade may indicate the presence of higher-grade tumor not detected at biopsy and could serve as a biomarker for monitoring disease progression of active surveillance patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA090381-11A1
Application #
8554554
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2001-04-01
Project End
2018-06-30
Budget Start
2013-09-23
Budget End
2014-06-30
Support Year
11
Fiscal Year
2013
Total Cost
$261,382
Indirect Cost
$86,703
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Chen, Eddy J; Sowalsky, Adam G; Gao, Shuai et al. (2015) Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res 21:1273-80
Labbé, D P; Zadra, G; Ebot, E M et al. (2015) Role of diet in prostate cancer: the epigenetic link. Oncogene 34:4683-91
Sowalsky, Adam G; Xia, Zheng; Wang, Liguo et al. (2015) Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol Cancer Res 13:98-106
Penney, Kathryn L; Sinnott, Jennifer A; Tyekucheva, Svitlana et al. (2015) Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev 24:255-60
Yu, Ziyang; Chen, Sen; Sowalsky, Adam G et al. (2014) Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res 20:1590-600
Crowe, Francesca L; Appleby, Paul N; Travis, Ruth C et al. (2014) Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies. J Natl Cancer Inst 106:
Cato, Laura; Neeb, Antje; Brown, Myles et al. (2014) Control of steroid receptor dynamics and function by genomic actions of the cochaperones p23 and Bag-1L. Nucl Recept Signal 12:e005
Sun, T; Wang, X; He, H H et al. (2014) MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene 33:2790-800
Priolo, Carmen; Pyne, Saumyadipta; Rose, Joshua et al. (2014) AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Res 74:7198-204
Kissick, Haydn T; Sanda, Martin G; Dunn, Laura K et al. (2014) Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. PLoS One 9:e93231

Showing the most recent 10 out of 149 publications